These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32728393)

  • 1. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
    Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
    Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Jing Z; Rui Z; Binglan Z
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
    Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
    Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
    Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
    Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
    J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
    Xu X; Yu Y; Liu M; Liang L; Liu T
    Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
    Abrahao ABK; Ko YJ; Berry S; Chan KKW
    Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
    Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
    Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
    Front Oncol; 2020; 10():587692. PubMed ID: 33282739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.
    Yan H; Liu J; Zhang Y; Chen S; Xu J; Gao D; Li H; Fang X; Wang Y; Wang H; Wang H
    J Gastrointest Oncol; 2024 Jun; 15(3):987-1001. PubMed ID: 38989408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
    Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
    J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
    Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
    Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis.
    Chen D; Wu YS; Lin H; Wang Y; Li L; Zhang T
    Cancer Manag Res; 2018; 10():2915-2924. PubMed ID: 30214286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
    Cao M; Zhou M; Zhang J
    J Chemother; 2020 Jul; 32(4):163-170. PubMed ID: 32081104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.